Tagessieger an der NASDAG - 500 Beiträge pro Seite
eröffnet am 09.06.03 20:03:54 von
neuester Beitrag 10.06.03 22:07:47 von
neuester Beitrag 10.06.03 22:07:47 von
Beiträge: 16
ID: 741.014
ID: 741.014
Aufrufe heute: 0
Gesamt: 1.022
Gesamt: 1.022
Aktive User: 0
Top-Diskussionen
| Titel | letzter Beitrag | Aufrufe |
|---|---|---|
| vor 25 Minuten | 7888 | |
| vor 17 Minuten | 5021 | |
| vor 1 Stunde | 2630 | |
| vor 1 Stunde | 2620 | |
| vor 1 Stunde | 2348 | |
| vor 22 Minuten | 2089 | |
| vor 38 Minuten | 2040 | |
| vor 37 Minuten | 1787 |
Meistdiskutierte Wertpapiere
| Platz | vorher | Wertpapier | Kurs | Perf. % | Anzahl | ||
|---|---|---|---|---|---|---|---|
| 1. | 1. | 17.810,76 | -1,53 | 239 | |||
| 2. | 3. | 163,50 | +0,85 | 94 | |||
| 3. | 2. | 9,1950 | -4,67 | 90 | |||
| 4. | 4. | 0,1920 | -1,03 | 84 | |||
| 5. | 6. | 0,0211 | -32,59 | 52 | |||
| 6. | 14. | 6,8500 | +1,66 | 51 | |||
| 7. | 34. | 0,6400 | -54,29 | 49 | |||
| 8. | 13. | 424,70 | -13,94 | 47 |
Feedback
Happy our in the Biotechsektor!!
Wondering When Biotech`s Happy Hour Will End
By Adam Feuerstein
Senior Writer
The foundation of the recent biotech recovery was laid last September, when President Bush picked adviser Mark McClellan to lead the rudderless Food and Drug Administration. From the moment of his appointment, McClellan, a doctor and noted health care economist,
made it clear that one of his top priorities would be to reinvigorate the regulatory agency and speed up the approval of new drugs.
At the time, few, if anyone, could`ve predicted just what an impact McClellan`s words would have on the biotech sector today, which is the midst of a heart-stopping rally.
The Amex Biotech Index (BTK:Amex - news - commentary - research - analysis) is now up about 43% for the year, or closer to 50% from the quagmire in which biotech investors found themselves back in mid-March. (An early Friday buying surge pumped the index over 500 before
profit-taking brought it back down.) The broader market has also rallied, of course, but the biotech sector has been leading the way.
Talk about a turnaround. The Amex Biotech Index fell 39% in 2002 -- its second consecutive year of losses -- so when the bell rang to begin trading in 2003, few investors were in the mood to predict good times ahead.
It would be foolish to ascribe 100% of the biotech recovery to McClellan`s leadership at the FDA; after all, there`s just so much
one guy can do. But a spat of drug approvals quickly left Wall Street with the impression that the regulatory agency -- once seen as a
hindrance -- was now ready to help.
"In hindsight, I think the first clue that we had a friendlier FDA was the Dec. 24 approval of Restasis," says David Chan of the Jennison Health Sciences Fund (formerly known as the Prudential Life Sciences Fund). Restasis is a drug developed by Allergan (AGN:NYSE - news - commentary - research - analysis) to treat chronic dry eye disease, but the data supporting the company`s filing were not
entirely conclusive, Chan says, and that could`ve tripped it up at the FDA. It didn`t.
After that, the FDA approved drugs from Genzyme General (GENZ:Nasdaq - news - commentary - research - analysis), AstraZeneca (AZN:NYSE - news - commentary - research - analysis) and Millennium Pharmaceuticals (MLNM:Nasdaq - news - commentary - research -
analysis), and it did so with alacrity. Investors, of course, jumped all over this news, concluding that the FDA would approve just about anything. Naturally, shares in biotech firms with drugs in front of the FDA have taken off.
For example, take a gander at the chart for CV Therapeutics (CVTX:Nasdaq - news - commentary - research - analysis). Six months
ago, this was a radioactive stock, because everyone was sure the FDA would reject its angina drug, Ranolazine. Today`s conventional wisdom
goes more like this: Puh-leeze, the FDA is a bunch of pushovers, right?
As if biotech needed a second wind to propel this rally, it got one in spades at the American Society of Clinical Oncology`s annual
meeting, better known as the Super Bowl of cancer research confabs. You`ve no doubt heard about the big winners: Genentech (DNA:NYSE -
news - commentary - research - analysis) and ImClone Systems (IMCLE:Nasdaq - news - commentary - research - analysis). The whole
meeting was a huge positive for biotechs, unlike the 2002 gathering, which, by comparison, had all the laughs of a funeral procession.
"At last year`s ASCO, investors were worried about their investments and the future of biotech," says SG Cowen biotech analyst Yaron
Werber. "At this year`s ASCO, we finally saw clear indication that biotech drugs, and not Big Pharma, are the drugs of the future."
All Good Things Come to an End
So, how long does this biotech rally last? So far, every attempt to call a top has been wrong. A lot of professional biotech traders
thought there`d be significant post-ASCO selling, just like in years past. Wrong.
Chan believes big mutual fund buyers are coming back to biotech in a big way to satiate their jones for growth stocks. For a long time, the sector`s biggest name, Amgen (AMGN:Nasdaq - news - commentary - research - analysis), was the only must-own tock, but now, fund managers have to own Genentech, too, he says, adding that this kind of muscle moving into the biotech sector is bound to keep the rally going. (It might just get Genentech to the $100 price target set by
UBS Warburg`s biotech analyst last week.)
Of course, you`d expect to hear this kind of happy talk from an investor who can only go long. But there are fundamental reasons to
support a continued biotech rally, including expected strong second-quarter earnings and more drugs on the FDA docket awaiting approval.
Drugs expected to get the nod soon include FluMist from MedImmune (MEDI:Nasdaq - news - commentary - research - analysis) and Xolair
from Genentech. If that`s not enough, plenty of clinical data will be released this summer, too. In the past, this would be cause for
concern, but these days it`s "don`t worry, be happy" time.
But biotech investors are also acting as though it`s 1999 all over again and all those painful lessons of the past two years were but a bad dream. You think the recent move in the sector is fantastic? How easy it is to forget that as late as September 2000, the Amex Biotech Index was above 800? For every sensible biotech investor who`s hedging his longs with options to limit potential losses, there are countless newbie biotech investors who are buying blindly, as if the party will never end.
Need proof? Just look at the frothiness found among small-cap biotechs. These ultra-risky stocks have surged far more than the big-
cap names. When dubious stocks double on the issuance of a questionable press release, you know that momentum investors and daytraders are chasing beta, not fundamentals. Yet someone, somewhere will be left holding the bag when the mania ends. Someone always
loses.
Says one biotech hedge-fund manager who has been through enough boom-and-bust cycles to know, "This is going to end badly for a lot of
people. The only question is when."
As I mentioned earlier, Friday`s profit-taking slowed the biotech juggernaut. We`ll know soon enough whether this is just the pause that refreshes or a signal that the rally is running out of steam.
Wondering When Biotech`s Happy Hour Will End
By Adam Feuerstein
Senior Writer
The foundation of the recent biotech recovery was laid last September, when President Bush picked adviser Mark McClellan to lead the rudderless Food and Drug Administration. From the moment of his appointment, McClellan, a doctor and noted health care economist,
made it clear that one of his top priorities would be to reinvigorate the regulatory agency and speed up the approval of new drugs.
At the time, few, if anyone, could`ve predicted just what an impact McClellan`s words would have on the biotech sector today, which is the midst of a heart-stopping rally.
The Amex Biotech Index (BTK:Amex - news - commentary - research - analysis) is now up about 43% for the year, or closer to 50% from the quagmire in which biotech investors found themselves back in mid-March. (An early Friday buying surge pumped the index over 500 before
profit-taking brought it back down.) The broader market has also rallied, of course, but the biotech sector has been leading the way.
Talk about a turnaround. The Amex Biotech Index fell 39% in 2002 -- its second consecutive year of losses -- so when the bell rang to begin trading in 2003, few investors were in the mood to predict good times ahead.
It would be foolish to ascribe 100% of the biotech recovery to McClellan`s leadership at the FDA; after all, there`s just so much
one guy can do. But a spat of drug approvals quickly left Wall Street with the impression that the regulatory agency -- once seen as a
hindrance -- was now ready to help.
"In hindsight, I think the first clue that we had a friendlier FDA was the Dec. 24 approval of Restasis," says David Chan of the Jennison Health Sciences Fund (formerly known as the Prudential Life Sciences Fund). Restasis is a drug developed by Allergan (AGN:NYSE - news - commentary - research - analysis) to treat chronic dry eye disease, but the data supporting the company`s filing were not
entirely conclusive, Chan says, and that could`ve tripped it up at the FDA. It didn`t.
After that, the FDA approved drugs from Genzyme General (GENZ:Nasdaq - news - commentary - research - analysis), AstraZeneca (AZN:NYSE - news - commentary - research - analysis) and Millennium Pharmaceuticals (MLNM:Nasdaq - news - commentary - research -
analysis), and it did so with alacrity. Investors, of course, jumped all over this news, concluding that the FDA would approve just about anything. Naturally, shares in biotech firms with drugs in front of the FDA have taken off.
For example, take a gander at the chart for CV Therapeutics (CVTX:Nasdaq - news - commentary - research - analysis). Six months
ago, this was a radioactive stock, because everyone was sure the FDA would reject its angina drug, Ranolazine. Today`s conventional wisdom
goes more like this: Puh-leeze, the FDA is a bunch of pushovers, right?
As if biotech needed a second wind to propel this rally, it got one in spades at the American Society of Clinical Oncology`s annual
meeting, better known as the Super Bowl of cancer research confabs. You`ve no doubt heard about the big winners: Genentech (DNA:NYSE -
news - commentary - research - analysis) and ImClone Systems (IMCLE:Nasdaq - news - commentary - research - analysis). The whole
meeting was a huge positive for biotechs, unlike the 2002 gathering, which, by comparison, had all the laughs of a funeral procession.
"At last year`s ASCO, investors were worried about their investments and the future of biotech," says SG Cowen biotech analyst Yaron
Werber. "At this year`s ASCO, we finally saw clear indication that biotech drugs, and not Big Pharma, are the drugs of the future."
All Good Things Come to an End
So, how long does this biotech rally last? So far, every attempt to call a top has been wrong. A lot of professional biotech traders
thought there`d be significant post-ASCO selling, just like in years past. Wrong.
Chan believes big mutual fund buyers are coming back to biotech in a big way to satiate their jones for growth stocks. For a long time, the sector`s biggest name, Amgen (AMGN:Nasdaq - news - commentary - research - analysis), was the only must-own tock, but now, fund managers have to own Genentech, too, he says, adding that this kind of muscle moving into the biotech sector is bound to keep the rally going. (It might just get Genentech to the $100 price target set by
UBS Warburg`s biotech analyst last week.)
Of course, you`d expect to hear this kind of happy talk from an investor who can only go long. But there are fundamental reasons to
support a continued biotech rally, including expected strong second-quarter earnings and more drugs on the FDA docket awaiting approval.
Drugs expected to get the nod soon include FluMist from MedImmune (MEDI:Nasdaq - news - commentary - research - analysis) and Xolair
from Genentech. If that`s not enough, plenty of clinical data will be released this summer, too. In the past, this would be cause for
concern, but these days it`s "don`t worry, be happy" time.
But biotech investors are also acting as though it`s 1999 all over again and all those painful lessons of the past two years were but a bad dream. You think the recent move in the sector is fantastic? How easy it is to forget that as late as September 2000, the Amex Biotech Index was above 800? For every sensible biotech investor who`s hedging his longs with options to limit potential losses, there are countless newbie biotech investors who are buying blindly, as if the party will never end.
Need proof? Just look at the frothiness found among small-cap biotechs. These ultra-risky stocks have surged far more than the big-
cap names. When dubious stocks double on the issuance of a questionable press release, you know that momentum investors and daytraders are chasing beta, not fundamentals. Yet someone, somewhere will be left holding the bag when the mania ends. Someone always
loses.
Says one biotech hedge-fund manager who has been through enough boom-and-bust cycles to know, "This is going to end badly for a lot of
people. The only question is when."
As I mentioned earlier, Friday`s profit-taking slowed the biotech juggernaut. We`ll know soon enough whether this is just the pause that refreshes or a signal that the rally is running out of steam.
Was ist denn NASDAG ? 
Was ist denn NASDAG ?
Hast ja recht aber deshalb musst Du das ja nicht gleich zweimal posten
Trading Spotlight
NAPRO
Ich denk mal das geht morgen so weiter, oder eroeffnet zumindest hoch. Bin mal auf ein paar von denen draufgesprungen.
#6
Und? Wolltest Du auch was sagen?
#6
Und? Wolltest Du auch was sagen?
@Ariminios
Es war einmal....
Es war einmal....
NPRO NAPRO BIOTHERAP 2:51pm 3.06 +1.75 +133.59% 9,249,663
OXGN OXIGENE INC 2:51pm 16.734 +8.254 +97.33% 22,547,324
PARS PHARMOS CP 2:51pm 2.06 +0.69 +50.36% 4,289,582 Chart,
OXGN OXIGENE INC 2:51pm 16.734 +8.254 +97.33% 22,547,324
PARS PHARMOS CP 2:51pm 2.06 +0.69 +50.36% 4,289,582 Chart,
Achtet auf Geron da sind eine Menge Leute short (etwa 20% der ausstehenden Aktien sind geshortet), die kriegen ganz nasse Füsse
ja und, donnerpower, lesen koenn wir selber.
Yep Geron sieht gut aus, meislo, musst ja dick verdient haben schon, Deine groesste Position hast Du mir gesagt, das war bei 6.04.
Yep Geron sieht gut aus, meislo, musst ja dick verdient haben schon, Deine groesste Position hast Du mir gesagt, das war bei 6.04.
nee halt mal, das war ja 5.04! WoW! Glueckwunsch!!
Und schon wieder stehen die biotechs ganzoben in der Gunst der Anleger
http://finance.yahoo.com/mnpg?e=o
http://finance.yahoo.com/mnpg?e=o
US-Biotech - Bis zu 135 Prozent Kursgewinn an einem Tag
Der Biotechsektor ist nichts für Anleger mit schwachen Nerven: Langwierige und damit kostenreiche Entwicklungsphasen, ungewisse Forschungsresultate und – oft genug – Pleiten selbst noch im letzten Entwicklungsstadium. Während des Bärenmarktes haben die Investoren dem Sektor in Scharen den Rücken gekehrt.
Offensichtlich aber sind sie nicht nachtragend, denn während der jüngsten Hausse an Wall Street gehören die Aktien von Biotechfirmen zu den absoluten Überfliegern. Positive Unternehmensnachrichten wie die von ImClone Systems [Nasdaq: IMCLE Kurs/Chart ] halten die Stimmung und damit auch die Aktienkurse auf hohem Niveau.
Bei den Blue Chips in der Branche ist nun ein wenig Ruhe eingekehrt, die Ausschläge werden geringer. Der Markt sucht indessen nach Werten aus der zweiten, dritten und sogar vierten Reihe – Hauptsache Nachholpotenzial. Der Montag stand an Wall Street denn auch ganz im Zeichen der Small- und Micro-Caps.
Kursgewinne zwischen 13 und 135 Prozent
Zwischen 13,2 Prozent und 135 Prozent betrugen die Kursgewinne bei Firmen wie NaPro [Nasdaq: NPRO Kurs/Chart ], OxiGENE [Nasdaq: OXGN Kurs/Chart ], Introgen [Nasdaq: INGN Kurs/Chart ] & Co.
Die Aktien von NaPro legten einen Spurt um 135 Prozent auf 3,08 Dollar hin, nachdem die Firma positive Forschungsresultate im Zusammenhang mit der Huntington-Krankheit veröffentlicht hatte.
OxiGENE reagierten mit einem Satz von 63 Prozent auf 13,80 Dollar hingegen auf die Ankündigung, dass das Unternehmen eines seiner Krebspräparate in klinischen Studien testen wird.
Die Kursgewinne der anderen Firmen resultierten entweder aus positiven Analystenkommentaren (Geron: +19 Prozent), Produktvorstellungen (Introgen: +13,2 Prozent) oder charttechnischen Gründen (EntreMed: +27 Prozent).
Suchen Sie noch nach aussichtsreichen Biotechaktien?
Fazit: Biotechaktien sind bei der Anlegergemeinde wieder gefragt und so lange der Aufwärtstrend an Wall Street hält, dürften die Notierungen weiter klettern. Wir empfehlen Ihnen aber jedes Investment – vor allem in niedrig kapitalisierten Unternehmen – mit engen Stopps abzusichern. Steigen Sie aus, wenn sich der Kurs nicht wie gewünscht entwickelt.
Wenn Sie noch auf der Suche nach interessanten Werten aus der Branche sind, dann verpassen Sie nicht den neuen Global Performance Premium. In der am Mittwoch (11.6.) erscheinenden Ausgabe stellen wir Ihnen 5 heiße Kandidaten vor, bei denen sich ein Einstieg lohnen dürfte.
© 10.06.2003 www.stock-world.de
Der Biotechsektor ist nichts für Anleger mit schwachen Nerven: Langwierige und damit kostenreiche Entwicklungsphasen, ungewisse Forschungsresultate und – oft genug – Pleiten selbst noch im letzten Entwicklungsstadium. Während des Bärenmarktes haben die Investoren dem Sektor in Scharen den Rücken gekehrt.
Offensichtlich aber sind sie nicht nachtragend, denn während der jüngsten Hausse an Wall Street gehören die Aktien von Biotechfirmen zu den absoluten Überfliegern. Positive Unternehmensnachrichten wie die von ImClone Systems [Nasdaq: IMCLE Kurs/Chart ] halten die Stimmung und damit auch die Aktienkurse auf hohem Niveau.
Bei den Blue Chips in der Branche ist nun ein wenig Ruhe eingekehrt, die Ausschläge werden geringer. Der Markt sucht indessen nach Werten aus der zweiten, dritten und sogar vierten Reihe – Hauptsache Nachholpotenzial. Der Montag stand an Wall Street denn auch ganz im Zeichen der Small- und Micro-Caps.
Kursgewinne zwischen 13 und 135 Prozent
Zwischen 13,2 Prozent und 135 Prozent betrugen die Kursgewinne bei Firmen wie NaPro [Nasdaq: NPRO Kurs/Chart ], OxiGENE [Nasdaq: OXGN Kurs/Chart ], Introgen [Nasdaq: INGN Kurs/Chart ] & Co.
Die Aktien von NaPro legten einen Spurt um 135 Prozent auf 3,08 Dollar hin, nachdem die Firma positive Forschungsresultate im Zusammenhang mit der Huntington-Krankheit veröffentlicht hatte.
OxiGENE reagierten mit einem Satz von 63 Prozent auf 13,80 Dollar hingegen auf die Ankündigung, dass das Unternehmen eines seiner Krebspräparate in klinischen Studien testen wird.
Die Kursgewinne der anderen Firmen resultierten entweder aus positiven Analystenkommentaren (Geron: +19 Prozent), Produktvorstellungen (Introgen: +13,2 Prozent) oder charttechnischen Gründen (EntreMed: +27 Prozent).
Suchen Sie noch nach aussichtsreichen Biotechaktien?
Fazit: Biotechaktien sind bei der Anlegergemeinde wieder gefragt und so lange der Aufwärtstrend an Wall Street hält, dürften die Notierungen weiter klettern. Wir empfehlen Ihnen aber jedes Investment – vor allem in niedrig kapitalisierten Unternehmen – mit engen Stopps abzusichern. Steigen Sie aus, wenn sich der Kurs nicht wie gewünscht entwickelt.
Wenn Sie noch auf der Suche nach interessanten Werten aus der Branche sind, dann verpassen Sie nicht den neuen Global Performance Premium. In der am Mittwoch (11.6.) erscheinenden Ausgabe stellen wir Ihnen 5 heiße Kandidaten vor, bei denen sich ein Einstieg lohnen dürfte.
© 10.06.2003 www.stock-world.de
@ 5
War keine Absicht.
War keine Absicht.
Zur Abwechslung mal die Tagesverlierer. Unzer Ihnen befinden sich viele der in letzter Zeit stark gestiegenen und hier om Board diskutierten Aktien der Biotechs
http://finance.yahoo.com/mnpl?e=o
http://finance.yahoo.com/mnpl?e=o
DurchsuchenBeitrag zu dieser Diskussion schreiben
Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie eine neue Diskussion.
Meistdiskutiert
| Wertpapier | Beiträge | |
|---|---|---|
| 228 | ||
| 96 | ||
| 90 | ||
| 76 | ||
| 53 | ||
| 49 | ||
| 48 | ||
| 44 | ||
| 42 | ||
| 33 |
| Wertpapier | Beiträge | |
|---|---|---|
| 28 | ||
| 27 | ||
| 27 | ||
| 26 | ||
| 26 | ||
| 24 | ||
| 23 | ||
| 22 | ||
| 21 | ||
| 21 |
